PBGM01
Pre-clinical- Indications
- GM1 gangliosidosis
Company intelligence / Profile preview
Ascendance Biomedical was a controversial biohacking biotech startup that sought to democratize access to experimental biomedical technologies by bypassing traditional regulatory processes. The company gained notoriety through public self-experimentation with unapproved gene therapies targeting herpes and HIV/AIDS. It also sponsored a completed Phase I clinical trial on autologous PRP infusions for ovarian rejuvenation but did not advance any programs through standard drug development pipelines. The company became inactive after the death of its founder Aaron Traywick amid internal disputes.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ascendance Biomedical.